Seattle, WA – According to filings with the U.S. Securities and Exchange Commission, Icosavax is raising $99,729,701.00 in new funding. Sources indicate as part of senior management President and Chief Executive Officer, Adam Simpson played a key role in securing the recent investment and it will aid in aggressively expanding the company, as well as broaden and accelerate product development.

About Icosavax

Icosavax is focused on developing safe and effective vaccines against infectious diseases that address important unmet medical needs and reduce healthcare costs. The company was founded on breakthrough computationally-designed virus like particle technology, exclusively licensed for a variety of infectious disease indications from the Institute for Protein Design at the University of Washington.

To learn more about Icosavax, visit http://www.icosavax.com/

Contact:
Adam Simpson, President and Chief Executive Officer
858-775-4523
https://www.linkedin.com/in/adam-simpson-a2871915/

SOURCE: http://www.intelligence360.io
Copyright (c) 2021 SI360 Inc. All rights reserved